The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NP-G2-044, an experimental treatment for pancreatic…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Treatment with DeltEx DRI, a cell therapy developed by In8bio, is prolonging survival outcomes among people with newly diagnosed…
GYNECOLOGICAL CANCER
Oral treatment for ovarian cancer put on FDA fast track
The U.S. Food and Drug Administration (FDA) has granted fast track designation to ETX-19477, an oral treatment for ovarian cancer…
Johnson & Johnson is now seeking regulatory approval in the European Union for Tecvayli (teclistamab) plus Darzalex…
All four adults with hard-to-treat acute myeloid leukemia (AML) who received treatment with a combination of Venclexta (venetoclax) and…
PANCREATIC CANCER
FDA grants orphan drug status to ARB1002 for pancreatic cancer
A new experimental treatment for pancreatic cancer, ARB1002, has been granted an orphan drug designation by the U.S. Food…
TTX-MC138, an RNA-based therapy from Transcode Therapeutics that’s in early clinical development, induced tumor cell death and prolonged survival…
GYNECOLOGICAL CANCER
Ernexa’s stem cell therapy could soon enter ovarian cancer trials
Ernexa Therapeutics is making headway on plans to start clinical testing of ERNA-101, its stem cell therapy designed to…
Medications designed to block a signaling protein called NOTCH3 — which plays a key role in the function and survival…
A Phase 3 clinical trial testing the experimental cancer vaccine galinpepimut-S (GPS) in people with acute myeloid leukemia (AML), a…